QL
AKBA icon

Quarry LP’s Akebia Therapeutics AKBA Stock Holding History

Quarry LP’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$257 Buy
+225
New +$268 ﹤0.01% 2260

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Quarry LP's AKBA Position: Q2 2026 in Review

Quarry LP opened a new position in Akebia Therapeutics (AKBA) in Q2 2026: 225 shares worth $257. The stake represents ﹤0.01% of the portfolio and ranks #2260 among its holdings.

171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Quarry LP held 225 shares of Akebia Therapeutics worth $257 as of Q2 2026.
  • Akebia Therapeutics was a new Quarry LP position in Q2 2026.
  • Akebia Therapeutics made up ﹤0.01% of Quarry LP's portfolio in Q2 2026, its #2260 holding.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Quarry LP's 13F filing for Q2 2026, filed 14 Aug 2026.